The Food and Drug Administration (FDA) has canceled its advisory panel meeting on flu vaccine formulations for the upcoming season. The abrupt cancellation has raised concerns among committee members and vaccine experts.
Paul Offit, a member of the FDA’s vaccine advisory committee and a professor of pediatrics at The Children’s Hospital of Philadelphia, expressed his concerns over the cancellation. He stated that the FDA provided no explanation for its decision.
This marks the second disruption of a vaccine advisory meeting since Robert F. Kennedy Jr., a well-known vaccine skeptic, assumed his role as Secretary of Health and Human Services (HHS). A mid-March meeting was also affected, adding to the growing uncertainty surrounding vaccine advisory processes.
Impact on Vaccine Policy and Public Health
The Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee meeting was recently postponed, citing the need for additional public comment. Reports suggest that Kennedy is reviewing the potential dismissal of current vaccine panel members.
Robert Hopkins, medical director of the National Foundation for Infectious Diseases, emphasized the critical nature of vaccine access and public confidence. In an email statement, he warned that disruptions in the advisory process could have significant public health consequences.
During his Senate confirmation hearings, Kennedy pledged to operate within existing vaccine safety evaluation programs. However, his history of vaccine skepticism, including his leadership of Children’s Health Defense—an organization that has promoted the debunked claim that vaccines cause autism—continues to fuel debate.
Each year, the FDA is responsible for identifying the influenza strains that will form the basis of flu vaccines for the upcoming fall-winter season. The World Health Organization (WHO) convenes experts annually in March to assess global flu strain data and provide recommendations.
Despite the FDA meeting’s cancellation, an agency spokesperson informed Reuters that guidance for the 2025-26 influenza vaccine strains would still be provided to manufacturers. The WHO’s upcoming meeting this week will determine the recommended strains for the 2025-26 Northern Hemisphere flu season. According to STAT, FDA and CDC officials will participate virtually, even as the U.S. navigates its position within the WHO following an executive order issued by former President Donald Trump for U.S. withdrawal.
The cancellation of the FDA’s advisory meeting underscores growing concerns about transparency and decision-making in vaccine policy under the current administration. Public health experts stress that consistent advisory procedures are essential to ensuring timely and effective vaccine distribution.
